Enhanced Outcomes in Type 2 Diabetes Patients With Acute Kidney Disease Through Thiazolidinedione
TZD demonstrated a notable reduction in mortality, cardiovascular events, and kidney-related adverse events among T2DM patients with AKD. These findings suggest a potential benefit of TZD usage for managing cardiovascular events in T2DM patients with AKD.
Authors
- Vin‐Cent Wu (ORCID: https://orcid.org/0000-0001-7935-0991)
- Li‐Yang Chang (ORCID: https://orcid.org/0009-0006-8898-5538)
- Hung‐Wei Liao (ORCID: https://orcid.org/0000-0003-3090-1937)
- Jui‐Yi Chen (ORCID: https://orcid.org/0000-0003-1376-7780)
Institutions
- National Taiwan University (TW)
- National Taiwan University Hospital (TW)
- Chi Mei Medical Center (TW)
- Wan Fang Hospital (TW)
Publication Details
- Journal
- The Journal of Clinical Endocrinology & Metabolism
- Published
- 2024-11-13
- DOI
- https://doi.org/10.1210/clinem/dgae796
- Citations
- 3
- Primary Topic
- Peroxisome Proliferator-Activated Receptors
- Type
- article
- Field-Weighted Citation Impact
- 0.70
Funders
- National Science Council
- National Taiwan University Hospital